Macular Telangiectasia Type 2 (MacTel)
3 clinical trials · Condition
◉ Watch Macular Telangiectasia Type 2 (MacTel)
| Record | Firm | Date |
|---|---|---|
| Study of Serine Supplementation to Protect Vision in MacTel (NCT07342439) | The Lowy Medical Research Institute Limited | 2026-09-01 |
| Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure Participants (NCT06971939) | Neurotech Pharmaceuticals | 2025-11-21 |
| A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol A (NCT03316300) | Neurotech Pharmaceuticals | 2017-11-24 |
Track Macular Telangiectasia Type 2 (MacTel) automatically
Every clearance here is in the API, with alerts when new ones post.